Hybrigenics receives €1.4 million to develop inecalcitol
This article was originally published in Scrip
Executive Summary
Hybrigenicshas received €1.4 million from OSEO, a French governmental development agency, to develop inecalcitol for prostrate cancer. The refundable subsidy will help the French functional proteomics firm and developer of cancer therapies to fund Phase II clinical trials through to their expected completion in mid-2009, and for regulatory requirements for authorising therapeutic efficacy studies. The company is conducting a Phase II tolerance trial of inecalcitol in combination with Sanofi-Aventis's Taxotere (docetaxel) for hormone-refractory prostate cancer. The oral dose of 300mg showed excellent tolerance, said Hybrigenics, and treatment with 600mg has just begun. The funding contributes 47.3% to total spending needed for the trial.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.